VGX-1027 – (6501-72-0)

VGX-1027, also known as GIT-27, is an orally active isoxazole compound with potent immunomodulatory properties. It functions as an immunomodulator by blocking the downstream signaling of Toll-like receptors TLR2, TLR4, and TLR6, thereby reducing the production of various cytokines, including interleukins and TNF-α. This compound has demonstrated anti-inflammatory effects in animal studies and is being investigated for its potential in treating conditions such as arthritis and lung inflammation.

In addition to its anti-inflammatory properties, VGX-1027 has shown promise in managing autoimmune diseases. Research indicates that it can prevent both organ-specific and systemic autoimmune diseases in murine models by modulating cytokine synthesis. The drug has also been studied for its antidiabetogenic effects, as it limits cytokine-mediated immunoinflammatory events.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/VGX-1027
https://pubchem.ncbi.nlm.nih.gov/compound/10798271
https://www.medchemexpress.com/VGX-1027.html
https://www.medkoo.com/products/6981
https://pubmed.ncbi.nlm.nih.gov/31610190/
https://www.sciencedirect.com/science/article/abs/pii/S0024320519308574